

Nanobiologics

Iqbal, Asif J

DOI:

[10.1093/cvr/cvz078](https://doi.org/10.1093/cvr/cvz078)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Iqbal, AJ 2019, 'Nanobiologics: a real game changer for targeted immunotherapy', *Cardiovascular Research*, vol. 115, no. 6, pp. e52-e53. <https://doi.org/10.1093/cvr/cvz078>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 23/07/2019

This is a pre-copyedited, author-produced version of an article accepted for publication in *Cardiovascular Research* following peer review.

The version of record:

Asif J Iqbal, Nanobiologics: a real game changer for targeted immunotherapy, *Cardiovascular Research*, Volume 115, Issue 6, 01 May 2019,

Pages e52–e53,

is available online at:

<https://doi.org/10.1093/cvr/cvz078>

<https://academic.oup.com/cvrcres/article/115/6/e52/5427124>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Biographical Sketch

Dr Asif Iqbal is a Birmingham Fellow in the Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham. He has been studying the role of inflammation in cardiovascular disease and how we can harness endogenous mediators to regulate this process. Inflammation has been the central theme throughout his research, with particular emphasis on the anti-inflammatory mechanisms at play in both acute and chronic immune models of inflammation. His doctoral training focused on the galectins and their role in regulating leukocyte trafficking and activation of immune cells. His post-doctoral research was centred on the role chemokines play in monocyte and macrophage recruitment in the context of atherosclerosis. Following his award of a Birmingham fellowship, he now aims to bring these themes together; to investigate the actions of the galectins in pre-clinical models of vascular inflammation and atherosclerosis, and the mechanisms by which they regulate monocyte recruitment and function.

Nanobiologics- a real game changer for targeted immunotherapy

Asif J Iqbal, PhD

Institute of Cardiovascular Sciences (ICVS), College of Medical and Dental Sciences,
University of Birmingham, Birmingham, B15 2TT, United Kingdom

Telephone: +441214144043

Email: a.j.iqbal@bham.ac.uk

Commentary on “Inhibiting inflammation with Myeloid cell-specific nanobiologics promotes organ transplant acceptance” by Braza *et al*, Immunity 2018

Organ transplantation has proven to be very effective in a variety of end stage diseases. Immunosuppressive agents prescribed to patients modestly improves graft survival but long term use can have detrimental side effects, leaving patients with increased risk of infection, cancer, and metabolic toxicity¹. Strategies targeting adaptive immune cell tolerance induction have proven promising², however long term graft survival rates still remain sub-optimal. More recently innate immune cells, including macrophages, NK cells and monocytes have been identified as key players in the initiation of allograft rejection^{3, 4}. The mechanisms by which macrophages mediate graft loss remain poorly understood.

Recently, a study by Braza *et al.*,⁵ identified a macrophage activation pathway linked to allograft rejection. The authors utilised a novel myeloid-specific nanoimmunotherapy to target graft infiltrating macrophages to promote long term organ transplant acceptance. Pro-inflammatory activation of macrophages by danger associated molecular patterns (DAMPs) vimentin and high mobility group box 1 (HMGB1) by dectin-1 and TLR4 activation has been previously shown^{6, 7}. Using an experimental heart transplantation mouse model, Braza *et al.*, found both vimentin and HMGB1 were upregulated in allograft infiltrating macrophages; raising the question whether these targets could promote “trained immunity”. Innate immune cells can acquire trained immunity or “innate immune memory”, whereby secondary non-specific challenge, after pre-exposure to certain inflammatory stimuli triggers epigenetic and metabolic changes, enhancing pro-inflammatory responses⁸. Monocytes pre-exposed to vimentin, followed by re-stimulation with HMGB1, increased pro-inflammatory IL-6 and TNF α production *in vitro*. Graft-infiltrating macrophages from dectin-1 and TLR4 deficient mouse heart allografts produced significantly lower levels of IL-6 and TNF α following *ex-vivo* stimulation.

To target trained macrophages therapeutically, Braza *et al.*, utilised myeloid specific high-density lipoproteins (HDL) nanobiologics⁹. The authors armed their nanobiologics with rapamycin, an mTOR inhibitor (termed mTORi-HDL), which has been shown to inhibit myeloid cell activation and pro-inflammatory cytokine production¹⁰. Heart allografts in recipient mice were shown to accumulate mTORi-HDL and its uptake preferentially by myeloid cells, namely macrophages. A treatment regime of three intravenous doses of mTORi-HDL was sufficient to prolong graft survival, compared to placebo control or mice treated with oral rapamycin. Following *ex vivo* stimulation it was shown that these macrophages had a marked reduction in pro-inflammatory cytokine production, suggesting trained macrophage responses were impaired because of mTORi-HDL treatment. Recipient allografts, blood and spleen were shown to have increased numbers of Ly6C^{Lo} macrophages, reported to have anti-inflammatory properties. The authors confirmed that Ly6C^{Lo} macrophages inhibited T cell proliferation and promoted regulatory T cell (Treg) expansion *in vitro*, in addition, mTORi-HDL allografts were shown to have significantly elevated Tregs counts. Irrespective of mTORi-HDL treatment, Ly6C^{Lo} macrophage depletion prior to transplantation resulted in early graft rejection. Allograft survival was restored following adoptive transfer of wild-type monocytes, reinforcing the view that the mTORi-HDL therapy requires Ly6C^{Lo} regulatory macrophages for successful organ transplant acceptance. Finally, the authors evaluated the impact of combinational therapy with mTORi-HDL and a CD40-CD40L targeting nanbiologic, TRAF6i-HDL¹¹. They found that short-term combination therapy with mTORi-HDL/ TRAF6i-HDL synergistically promoted long-term allograft survival, and significantly outperformed either monotherapy.

The study by Braza *et al.*, clearly highlights the importance of innate immune signalling in driving trained immunity and excessive inflammation. Taking atherosclerosis as an example, Bekkering *et al.*,¹² found that exposing monocytes to a low concentration of oxLDL drove a trained proatherogenic macrophage phenotype characterised by increased pro-inflammatory cytokine production and foam cell formation. A review by Zhang and colleagues¹³ emphasised the importance of trained macrophage activation pathways in pathological conditions such as cardiac remodelling and ischaemic heart disease. A recent review by Kusters and colleagues¹⁴ reiterated the importance of immune checkpoint molecules and their potential as therapeutic targets in atherosclerosis. The concept of targeting immune checkpoint molecules, such as CD40-CD40L, as chosen by Braza *et al.*, or others, like CD80/86-CD28, is not a novel concept in of itself. However, the use of nanobiologics to successfully administer high local doses of immunosuppressive agents while limiting systemic toxicity proves to be a very attractive modality of treatment and could very well

breathe life into current treatment regimens and combinatorial therapies in the treatment of multiple chronic inflammatory diseases.

Funding

The author would like to acknowledge support from the Birmingham Fellowship scheme and Academy of Medical Sciences Springboard scheme (SBF003\1156)

References

1. Fishman JA. Infection in Organ Transplantation. *Am J Transplant.* 2017;17:856-879.
2. Page EK, Dar WA and Knechtle SJ. Tolerogenic therapies in transplantation. *Front Immunol.* 2012;3:198.
3. Liu W, Xiao X, Demirci G, Madsen J and Li XC. Innate NK cells and macrophages recognize and reject allogeneic nonself in vivo via different mechanisms. *J Immunol.* 2012;188:2703-11.
4. Oberbarnscheidt MH, Zeng Q, Li Q, Dai H, Williams AL, Shlomchik WD, Rothstein DM and Lakkis FG. Non-self recognition by monocytes initiates allograft rejection. *J Clin Invest.* 2014;124:3579-89.
5. Braza MS, van Leent MMT, Lameijer M, Sanchez-Gaytan BL, Arts RJW, Perez-Medina C, Conde P, Garcia MR, Gonzalez-Perez M, Brahmachary M, Fay F, Kluza E, Kossatz S, Dress RJ, Salem F, Rialdi A, Reiner T, Boros P, Strijkers GJ, Calcagno CC, Ginhoux F, Marazzi I, Lutgens E, Nicolaes GAF, Weber C, Swirski FK, Nahrendorf M, Fisher EA, Duivenvoorden R, Fayad ZA, Netea MG, Mulder WJM and Ochando J. Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant Acceptance. *Immunity.* 2018;49:819-828 e6.
6. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, Lu B, Chavan S, Rosas-Ballina M, Al-Abed Y, Akira S, Bierhaus A, Erlandsson-Harris H, Andersson U and Tracey KJ. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. *Proc Natl Acad Sci U S A.* 2010;107:11942-7.
7. Thiagarajan PS, Yakubenko VP, Elson DH, Yadav SP, Willard B, Tan CD, Rodriguez ER, Febbraio M and Cathcart MK. Vimentin is an endogenous ligand for the pattern recognition receptor Dectin-1. *Cardiovasc Res.* 2013;99:494-504.
8. Netea MG and van der Meer JW. Trained Immunity: An Ancient Way of Remembering. *Cell Host Microbe.* 2017;21:297-300.
9. Mulder WJM, van Leent MMT, Lameijer M, Fisher EA, Fayad ZA and Perez-Medina C. High-Density Lipoprotein Nanobiologics for Precision Medicine. *Acc Chem Res.* 2018;51:127-137.
10. Ballou LM and Lin RZ. Rapamycin and mTOR kinase inhibitors. *J Chem Biol.* 2008;1:27-36.
11. Guillems M, Mildner A and Yona S. Developmental and Functional Heterogeneity of Monocytes. *Immunity.* 2018;49:595-613.
12. Bekkering S, Quintin J, Joosten LA, van der Meer JW, Netea MG and Riksen NP. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. *Arterioscler Thromb Vasc Biol.* 2014;34:1731-8.
13. Zhang Y, Huang Z and Li H. Insights into innate immune signalling in controlling cardiac remodelling. *Cardiovasc Res.* 2017;113:1538-1550.
14. Kusters PJH, Lutgens E and Seijkens TTP. Exploring immune checkpoints as potential therapeutic targets in atherosclerosis. *Cardiovasc Res.* 2018;114:368-377.